Innovations in Oral Solid Drug Delivery and Advances in nanotechnology, controlled formulations & peptide delivery

Innovations in Oral Solid Drug Delivery and Advances in nanotechnology, controlled formulations & peptide delivery

This report concentrates on innovations in oral solid dose delivery systems (OSDDS) with an emphasis on the links between start up companies and academic collaborations. It deals with the impact of the difficult economic climate with the restriction on funding and opportunities for partnering projects.

Developments are assessed in relation to understanding the dynamics of the market. For instance the report discusses the loss of patent protection for blockbuster drugs peaking between 2007-2012, loss of patent protection for the first-generation of OSDDS in the last few years, the dearth of NCEs coming through the pipeline and puts new developments in the context of a market that is seeing a decline in its value in some therapeutic areas. It identifies the drivers for new OSDDS and the issues surrounding them.

A key theme is the transition of peptides and proteins from intravenous to oral delivery. The report looks at the competitive landscape, making reference to sales and market dynamics. A recurring theme is the reformulation of old generic drugs to get over inadequacies in the original drug for instance: low solubility, bioavailability, short duration of action, high side effect potential, poor stability, poor absorption following oral administration, bitter or unpleasant taste, narrow GI absorption window and inter- and intra-patient variability in absorption.

With a growing geriatric population and with people living longer much of the emphasis is on development of OSDDS drugs to more effectively treat diseases of an aging population such as Alzheimer’s disease, Parkinson’s disease, type 2 diabetes and obesity, osteoporosis, cancer and rheumatoid arthritis, etc. Often these treatments have side effects, problems with dosing and short duration of action or have to be administered by injection which reduces their acceptability.

Key features of this report

* Analysis of innovative platform technologies, companies and product development pipelines involved in transitioning injectable to oral drug delivery.
* Review of companies and technologies developing oral formulations of peptides and small proteins, highlighting stage of development, indications and competitive nature of the area.
* Providing an understanding of the specific problems involved in transitioning intravenous peptides to oral delivery and the mechanisms of crossing the GI mucosa, together with a review of approaches utilized.
* Analysis of sales data, growth rates, market share, generic entrants, new products for therapeutic areas in which the new products using the new technologies will compete.
* Assessment of market potential of the new osdds products in relation to the current market and competitors.

Scope of this report

* Get a comprehensive understanding of the range of new innovative osdds technologies and how they can overcome problems with the original active ingredient.
* Identify potential novel technologies which might allow you to overcome a problem with your own drug portfolio or which would allow you to extend your products’ franchise in the market place.
* Allow you to identify potential licensing opportunities or collaborations with innovative technology companies and assess the potential with respect to recent products commercialized.
* Allows you to identify which companies and which therapeutic areas are successful in gaining backing for their technologies and those that are not.
* Identify the time scales, hurdles and progress in developing new innovative technologies such as nanotechnologies/nanomedicines, oral peptides and proteins, new prodrugs and assess market factors affecting the developments and their success/failure.

Key Market Issues

* Asthe population ages and those elderly people live longer there is a

Aarkstore Enterprise -Advances in nanotechnology – Innovations in Oral Solid Drug Delivery: controlled formulations & peptide delivery-Aarkstore E

Aarkstore Enterprise -Advances in nanotechnology – Innovations in Oral Solid Drug Delivery: controlled formulations & peptide delivery-Aarkstore E

Innovations in Oral Solid Drug Delivery: Advances in nanotechnology, controlled formulations & peptide delivery

 
Table of Contents : 

Innovations in oral solid drug delivery
Executive summary 18
Market overview, dynamics and outlook 18
Advances in nanotechnology 19
Innovations in transitioning injectables to oral delivery 20
Advances in delayed & controlled release delivery 21
Advances in oral prodrug delivery 22
Advances in taste masking technologies 23
Innovative companies 24
Chapter 1 Market overview, dynamics and outlook 28
Summary 28
Market overview 29
Market dynamics 31
Key indications 33
Key trends 38
Nanomedicine 38
Transitioning from injectables 39
Prodrugs 40
Chrono release 41
ODT 41
OSF 42
Funding issues 42
Poor patient compliance 42
Injections 42
Poor absorbption 42
Pediatric 43
Geriatric 43
Solubility and variable absorption 43
Reduction of side effect profiles 44
Non-invasive protein delivery 45
Transition from injectables to preferred route of oral drug delivery 45
Directed delivery and delayed delivery to reduce side effect potential 46
Formulation technologies for poorly soluble compounds 46
Taste masking for pediatric and geriatric formulations 47
Competitive landscape 48
Conclusions and key findings 50
Chapter 2 Advances in nanotechnology 56
Summary 56
Introduction 57
Nanotechnology platforms with application for oral drug delivery 59
Self-Emulsifying Controlled Release Tablet system (SECRET) 59
Technology 59
Application 59
Biotransport nanomedicine technology 60
Technology 60
Application 60
Nanobodies 61
Technology 61
Application 61
NanoDel nanoparticles 62
Technology 62
Application 62
P-gpMask 63
Technology 63
Application 64
NanoDRY and NanoCOAT 64
Technology 64
Application 64
Solumer 67
Technology 67
Application 67
Nanocells 69
Technology 69
Application 70
Polymeric Nano-Delivery System (PNDS) 70
Technology 70
Application 71
FluidCrystal NP Oral nanoparticles 71
Technology 71
Application 72
CaP Technology and BioOral 72
Technology 72
Application 73
Nab Technology and Protospheres 73
Technology 73
Application 73
NanoCrystal Technology 74
Technology 74
Application 74
Bioral 75
Technology 75
Application 75
Squalenoyl nanoparticles 76
NanoMega 76
NOD Pharmaceutical 76
Chapter 3 Innovations in transitioning injectables to oral delivery 80
Summary 80
Introduction 81
Drivers 81
Patient acceptability & compliance 81
Cost savings 81
Restraints 82
Advances in injectable delivery 82
Challenges of oral drug delivery 83
Technologies used in oral drug delivery of peptides and proteins 84
Enzyme inhibitors 84
Permeation enhancers 85
Mucoadhesives 85
Encapsulation technologies 85
M-cell targeting 86
Competitive landscape 86
Osteoporosis and other bone related conditions 88
Calcitonin 88
Current therapies & market landscape 89
Oral products in development 91
Parathyroid hormone 94
Current therapies & market landscape 94
Oral products in development 96
Combined oral calcitonin and PTH approaches 97
Bisphosphonates 97
Current therapies & market landscape 97
Novel oral products in development 99
Diabetes and other metabolic diseases 104
Oral insulin 104
Oramed Pharmaceuticals 104
Biocon Ltd 105
Emisphere Technologies 105
Diabetology 106
NOD Pharmaceuticals 106
Access Pharmaceuticals 107
NanoMega Medical Corporation 107
Biodel Inc 108
Metabolic Pharmaceuticals Ltd